Primary Aldosteronism

Also known as: Primary hyperaldosteronism / Conn's syndrome / Idiopathic aldosteronism (disorder) / Conn Syndrome / Primary hyperaldosteronism (disorder)

DrugDrug NameDrug Description
DB12221CanrenoneAn antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).
DrugDrug NameTargetType
DrugDrug NamePhaseStatusCount
DB00381Amlodipine2Completed1
DB01590Everolimus2Completed1
DB00700Eplerenone4Recruiting1
DB16165Finerenone4Not Yet Recruiting2
DB16165Finerenone4Recruiting1
DB00421Spironolactone4Not Yet Recruiting2
DB01284Tetracosactide4Unknown Status1
DB00594AmilorideNot AvailableCompleted1
DB01197CaptoprilNot AvailableUnknown Status1
DB00568CinnarizineNot AvailableActive Not Recruiting1
DB01285CorticotropinNot AvailableCompleted1
DB01234DexamethasoneNot AvailableCompleted1
DB00700EplerenoneNot AvailableCompleted2
DB15207EsaxerenoneNot AvailableCompleted1
DB01115NifedipineNot AvailableActive Not Recruiting1
DB00421SpironolactoneNot AvailableCompleted2
DB00421SpironolactoneNot AvailableRecruiting2